

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

### *APPLICATION NUMBER:*

**761149Orig1s000**

*Trade Name:* ENSPRYNG injection

*Generic or Proper Name:* satralizumab-mwge

*Sponsor:* Genentech, Inc.

*Approval Date:* August 14, 2020

*Indication:* Enspryng is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

# CENTER FOR DRUG EVALUATION AND RESEARCH

## 761149Orig1s000

### CONTENTS

#### Reviews / Information Included in this NDA Review.

<b>Approval Letter</b>	<b>X</b>
<b>Other Action Letters</b>	
<b>Labeling</b>	<b>X</b>
<b>REMS</b>	
<b>Summary Review</b>	<b>X</b>
<b>Officer/Employee List</b>	<b>X</b>
<b>Office Director Memo</b>	
<b>Cross Discipline Team Leader Review</b>	
<b>Clinical Review(s)</b>	<b>X</b>
<b>Product Quality Review(s)</b>	<b>X</b>
<b>Non-Clinical Review(s)</b>	<b>X</b>
<b>Statistical Review(s)</b>	<b>X</b>
<b>Clinical Microbiology / Virology Review(s)</b>	
<b>Clinical Pharmacology Review(s)</b>	<b>X</b>
<b>Other Reviews</b>	<b>X</b>
<b>Risk Assessment and Risk Mitigation Review(s)</b>	<b>X</b>
<b>Proprietary Name Review(s)</b>	<b>X</b>
<b>Administrative/Correspondence Document(s)</b>	<b>X</b>

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**761149Orig1s000**

**APPROVAL LETTER**



BLA 761149

**BLA APPROVAL**

Genentech, Inc.  
Attention: Deborah Urquhart, PhD  
Principal Program Director  
1 DNA Way  
South San Francisco, CA 94080

Dear Dr. Urquhart:

Please refer to your biologics license application (BLA) dated and received August 15, 2019, and your amendments, submitted under section 351(a) of the Public Health Service Act for Enspryng (satralizumab-mwge) injection.

### **LICENSING**

We have approved your BLA for Enspryng (satralizumab-mwge) injection effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce Enspryng under your existing Department of Health and Human Services U.S. License No. 1048. Enspryng is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

### **MANUFACTURING LOCATIONS**

Under this license, you are approved to manufacture the satralizumab-mwge (b) (4) drug substance at Chugai Pharma Manufacturing Co., Ltd., Ukima, Japan, and to test at Chugai Pharma Manufacturing Co., Ltd., Ukima, Japan and Chugai Pharma Manufacturing Co., Ltd., Utsunomiya City, Japan. The formulated drug product will be manufactured, filled, and tested at Chugai Pharma Manufacturing Co., Ltd., in Utsunomiya City, Japan, and tested at Chugai Pharma Manufacturing Co., Ltd., Utsunomiya City, Japan. The final formulated drug product will be assembled, labeled, packaged, and tested at F. Hoffmann-La Roche, Ltd., in Kaiseraugst, Switzerland.

You may label your product with the proprietary name, Enspryng, and market it in a 120 mg/mL single-dose prefilled syringe.

### **DATING PERIOD**

The dating period for Enspryng shall be 24 months from the date of manufacture when stored at 2-8°C. The date of manufacture shall be defined as the date of final sterile

filtration of the formulated drug product. The dating period for your drug substance shall be (b) (4) months from the date of manufacture when stored at (b) (4) °C.

We have approved the stability protocols in your BLA for the purpose of extending the expiration dating period of your drug substance and drug product under 21 CFR 601.12.

### **FDA LOT RELEASE**

You are not currently required to submit samples of future lots of Enspryng to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Enspryng, or in the manufacturing facilities, will require the submission of information to your BLA for our review and written approval, consistent with 21 CFR 601.12.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on August 12, 2020, with the exception that the expiration

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

date format will be presented as MM YYYY, as soon as they are available, but no more than 30 days after they are printed. Please submit the labels and labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved BLA 761149**” Approval of this submission by FDA is not required before the labeling is used.

### **ADVISORY COMMITTEE**

Your application for Enspryng (satralizumab-mwge) was not referred to an FDA advisory committee because the safety profile is acceptable for NMOSD in adult patients who are anti-AQP4 antibody positive, the clinical trial designs are acceptable, the efficacy findings are clear, and outside expertise was not necessary; there were no controversial issues that would benefit from advisory committee discussion.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

### **POSTMARKETING REQUIREMENTS UNDER 505(o)**

Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (FDCA) authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to identify an unexpected serious risk of adverse maternal, fetal, and infant outcomes resulting from the use of Enspryng (satralizumab-mwge) during pregnancy.

Furthermore, the active postmarket risk identification and analysis system as available under section 505(k)(3) of the FDCA will not be sufficient to assess this serious risk.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following study:

**U.S. Food and Drug Administration**  
Silver Spring, MD 20993  
[www.fda.gov](http://www.fda.gov)

3920-1 A worldwide single-arm pregnancy safety study to collect and analyze information for a minimum of 10 years on pregnancy complications and birth outcomes in women exposed to Enspryng (satralizumab-mwge) during pregnancy in patients with neuromyelitis optica spectrum disorder (NMOSD). Provide a complete protocol that includes details regarding how you plan to encourage patients and providers to report pregnancy exposures, measures to ensure complete data capture regarding pregnancy outcomes and any adverse effects in offspring, and plans for comprehensive data analysis.

The timetable you submitted on August 12, 2020, states that you will conduct this study according to the following schedule:

Draft Protocol Submission:	04/2021
Final Protocol Submission:	12/2021
Annual Interim Report Submissions:	12/2022
	12/2023
	12/2024
	12/2025
	12/2026
	12/2027
	12/2028
	12/2029
	12/2030
	12/2031
Study Completion:	12/2032
Final Report Submission:	12/2033

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.<sup>3</sup>

Submit clinical protocol(s) to your IND 118183 with a cross-reference letter to this BLA. Submit nonclinical and chemistry, manufacturing, and controls protocols and all final report(s) to your BLA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate:

**Required Postmarketing Protocol Under 505(o), Required Postmarketing Final Report Under 505(o), Required Postmarketing Correspondence Under 505(o).**

---

<sup>3</sup> See the guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (October 2019)*.

<https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

U.S. Food and Drug Administration

Silver Spring, MD 20993

[www.fda.gov](http://www.fda.gov)

Submission of the protocol(s) for required postmarketing observational studies to your IND is for purposes of administrative tracking only. These studies do not constitute clinical investigations pursuant to 21 CFR 312.3(b) and therefore are not subject to the IND requirements under 21 CFR part 312 or FDA's regulations under 21 CFR parts 50 (Protection of Human Subjects) and 56 (Institutional Review Boards).

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 601.70, requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 601.70 to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 601.70. We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

### **REQUESTED PHARMACOVIGILANCE**

We request that you perform enhanced postmarketing surveillance for cases of serious and opportunistic infections including fatal infections, hepatotoxicity, and thrombocytopenia in patients treated with Enspryng (satralizumab-mwge). Submit individual reports as 15-day expedited reports to your BLA and directly to the Division of Neurology 2. In addition, include comprehensive summaries and analyses of these events quarterly as part of your required postmarketing safety reports (i.e., the Periodic Adverse Experience Report required under 21 CFR 600.80(c)(2) or the ICH E2C Periodic Benefit-Risk Evaluation Report [PBRER] format). In the analysis of each case, provide an assessment of causality, along with information about dose, duration of therapy, time of event in relation to duration of therapy, associated signs and symptoms, concomitant therapies, treatment given for the event, and outcome of each event. For cases of serious and opportunistic infections, provide all relevant laboratory assessments, including total white blood cell count with differential, lymphocyte subtype counts, immunoglobulin levels, microbiological diagnostics results (e.g., microscopy, culture, serology, molecular assays) and radiographic findings related to the locus of infection, if available. Targeted data collection tools should be used to assess cases of thrombocytopenia and cases of potential drug-induced liver injury.



## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>4</sup>

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [FDA.gov](http://FDA.gov).<sup>5</sup> Information and Instructions for completing the form can be found at [FDA.gov](http://FDA.gov).<sup>6</sup>

## **REPORTING REQUIREMENTS**

You must submit adverse experience reports under the adverse experience reporting requirements for licensed biological products (21 CFR 600.80).

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements for licensed biological products (21 CFR 600.81).

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Compliance Risk Management and Surveillance  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

---

<sup>4</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>6</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Compliance Risk Management and Surveillance  
10903 New Hampshire Avenue, Bldg. 51, Room 4207  
Silver Spring, MD 20903

### **POST APPROVAL FEEDBACK MEETING**

New molecular entities and new biological products qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, contact CDR Candido Alicea, Regulatory Project Manager, at (240) 402-8310.

Sincerely,

*{See appended electronic signature page}*

Billy Dunn, MD  
Director (Acting)  
Office of Neuroscience  
Center for Drug Evaluation and Research

#### **ENCLOSURES:**

- Content of Labeling
  - Prescribing Information
  - Medication Guide
  - Instructions for Use

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

WILLIAM H Dunn  
08/14/2020 08:09:48 PM